• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球消除宫颈癌的战略方法:最新综述与呼吁国家行动

Strategic approaches for global cervical cancer elimination: An update review and call for national action.

作者信息

Wilailak Sarikapan, Kengsakul Malika, Kehoe Sean

机构信息

Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Department of Obstetrics and Gynecology, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, Thailand.

出版信息

Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1:120-128. doi: 10.1002/ijgo.70276.

DOI:10.1002/ijgo.70276
PMID:40908769
Abstract

Cervical cancer remains a major health burden, particularly in low- and middle-income countries, despite being one of the most preventable cancers. WHO's 90-70-90 targets aim to eliminate cervical cancer globally by 2030. These targets include 90% of girls fully vaccinated with the HPV vaccine by the age of 15 years, 70% of women screened using a high-performance test by the age of 35 years and again by 45 years, and 90% of women with cervical disease receiving appropriate treatment. Achieving these goals requires coordinated national efforts to strengthen health systems, ensure equitable access to care, and integrate cervical cancer control into broader health policies. This review outlines key strategic approaches, including the transition from conventional screening methods to HPV-based screening, the adoption of innovative triage techniques, the implementation of single-dose HPV vaccination, and the integration of primary treatment with palliative care. The strategy places strong emphasis on addressing health inequities, enhancing monitoring systems, and fostering partnerships between governments, non-governmental organizations, and the private sector. With concerted global and national action, the elimination of cervical cancer is not only a possibility but an imminent reality.

摘要

宫颈癌仍然是一项重大的健康负担,尤其是在低收入和中等收入国家,尽管它是最可预防的癌症之一。世界卫生组织的90-70-90目标旨在到2030年在全球消除宫颈癌。这些目标包括90%的女孩在15岁前完全接种人乳头瘤病毒(HPV)疫苗,70%的女性在35岁时使用高效检测方法进行筛查,并在45岁时再次筛查,以及90%患有宫颈疾病的女性接受适当治疗。实现这些目标需要国家作出协调一致的努力,以加强卫生系统,确保公平获得医疗服务,并将宫颈癌控制纳入更广泛的卫生政策。本综述概述了关键的战略方法,包括从传统筛查方法向基于HPV的筛查过渡、采用创新的分流技术、实施单剂量HPV疫苗接种,以及将初级治疗与姑息治疗相结合。该战略高度重视解决卫生不公平问题、加强监测系统以及促进政府间、非政府组织和私营部门之间的伙伴关系。通过全球和国家的协同行动,消除宫颈癌不仅是可能的,而且即将成为现实。

相似文献

1
Strategic approaches for global cervical cancer elimination: An update review and call for national action.全球消除宫颈癌的战略方法:最新综述与呼吁国家行动
Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1:120-128. doi: 10.1002/ijgo.70276.
2
Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis.移民人群中人类乳头瘤病毒疫苗接种的驱动因素及提高覆盖率的干预措施:一项系统评价和荟萃分析
Lancet Public Health. 2025 Aug;10(8):e693-e711. doi: 10.1016/S2468-2667(25)00148-3.
3
HPV DNA screening and vaccination strategies in Tunisia.突尼斯的人乳头瘤病毒DNA筛查与疫苗接种策略
Sci Rep. 2025 Jul 31;15(1):27916. doi: 10.1038/s41598-025-13423-3.
4
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.接种人乳头瘤病毒预防性疫苗以预防宫颈癌及其癌前病变。
Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3.
5
Cervical Cancer Screening, HPV Vaccination, and Cervical Cancer Elimination.宫颈癌筛查、人乳头瘤病毒疫苗接种与宫颈癌消除
JAMA Netw Open. 2025 Aug 1;8(8):e2526683. doi: 10.1001/jamanetworkopen.2025.26683.
6
Factors that influence caregivers' and adolescents' views and practices regarding human papillomavirus (HPV) vaccination for adolescents: a qualitative evidence synthesis.影响照顾者和青少年对青少年人乳头瘤病毒(HPV)疫苗接种的看法及做法的因素:一项定性证据综合分析
Cochrane Database Syst Rev. 2025 Apr 15;4(4):CD013430. doi: 10.1002/14651858.CD013430.pub2.
7
Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.将人乳头瘤病毒(HPV)疫苗接种计划与强化宫颈癌筛查及治疗相结合:一项系统评价
Vaccine. 2022 Mar 31;40 Suppl 1:A116-A123. doi: 10.1016/j.vaccine.2021.11.013. Epub 2021 Dec 1.
8
Cervical cancer screening in Europe and Romania: a review of policies, progress, and persistent disparities.欧洲及罗马尼亚的宫颈癌筛查:政策、进展与持续存在的差异综述
J Med Life. 2025 Jul;18(7):604-607. doi: 10.25122/jml-2025-0099.
9
Human papillomavirus (HPV) vaccination in women with conisation.锥切术后女性的人乳头瘤病毒(HPV)疫苗接种
Cochrane Database Syst Rev. 2025 Sep 8;9(9):CD016121. doi: 10.1002/14651858.CD016121.
10
Progress and Challenges in Canada's Path Toward the Elimination of Cervical Cancer.加拿大消除宫颈癌道路上的进展与挑战。
Curr Oncol. 2024 Sep 29;31(10):5850-5861. doi: 10.3390/curroncol31100435.

引用本文的文献

1
FIGO Cancer Report 2025: Transforming gynecologic oncology through global equity, technological innovation, and preventive strategies.《国际妇产科联盟2025年癌症报告:通过全球公平、技术创新和预防策略变革妇科肿瘤学》
Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1(Suppl 1):4-5. doi: 10.1002/ijgo.70428. Epub 2025 Aug 2.

本文引用的文献

1
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.一种具有联合预防和治疗活性的安全且增强型多类型HPV L2-E7纳米颗粒疫苗。
NPJ Vaccines. 2024 Jun 26;9(1):119. doi: 10.1038/s41541-024-00914-z.
2
Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting.在中低收入国家环境下,二价、四价或九价 HPV 疫苗一剂或两剂接种的成本效益分析。
J Gynecol Oncol. 2024 Nov;35(6):e85. doi: 10.3802/jgo.2024.35.e85. Epub 2024 Apr 18.
3
Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination.
英国 HPV 疫苗接种的成本效益:二价与九价 HPV 疫苗接种的单剂量与双剂量比较。
Am J Prev Med. 2024 Aug;67(2):231-240. doi: 10.1016/j.amepre.2024.03.008. Epub 2024 Mar 18.
4
Correlation between P16/Ki67 in cervical cytology and diagnosis of cervical intraepithelial neoplasia 2-3 in Thai women infected with high-risk types of human papillomavirus.泰国高危型人乳头瘤病毒感染女性宫颈细胞学中P16/Ki67与宫颈上皮内瘤变2-3级诊断的相关性
Taiwan J Obstet Gynecol. 2024 Mar;63(2):192-198. doi: 10.1016/j.tjog.2024.01.014.
5
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.在坦桑尼亚,比较 9-14 岁女孩接种一剂 HPV 疫苗(DoRIS)与肯尼亚 15-20 岁年轻女性接种一剂 HPV 疫苗(KEN SHE):一项免疫桥接分析随机对照试验。
Lancet Glob Health. 2024 Mar;12(3):e491-e499. doi: 10.1016/S2214-109X(23)00586-7.
6
Single dose HPV vaccine in achieving global cervical cancer elimination.单剂量人乳头瘤病毒疫苗在实现全球消除宫颈癌方面的作用
Lancet Glob Health. 2024 Mar;12(3):e360-e361. doi: 10.1016/S2214-109X(24)00009-3.
7
Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV.HIV 感染者的宫颈筛查、分流和治疗策略的获益与危害。
Nat Med. 2023 Dec;29(12):3059-3066. doi: 10.1038/s41591-023-02601-3. Epub 2023 Dec 12.
8
p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.p16/Ki67 双染分流检测与有限基因分型在基于人乳头瘤病毒的原发性宫颈癌筛查中细胞学检查的比较。
J Med Virol. 2023 Nov;95(11):e29271. doi: 10.1002/jmv.29271.
9
Artificial intelligence for cervical cancer screening: Scoping review, 2009-2022.人工智能在宫颈癌筛查中的应用:2009-2022 年的范围综述。
Int J Gynaecol Obstet. 2024 May;165(2):566-578. doi: 10.1002/ijgo.15179. Epub 2023 Oct 9.
10
An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.一剂次人乳头瘤病毒疫苗研究、免疫桥接及体液免疫反应的最新进展——会议报告
Prev Med Rep. 2023 Aug 14;35:102368. doi: 10.1016/j.pmedr.2023.102368. eCollection 2023 Oct.